Literature DB >> 6466545

Effect of adriamycin on CFUGM at plasma concentrations found following therapeutic infusions.

R Bailey-Wood, C M Dallimore, J A Whittaker.   

Abstract

The effect of adriamycin on human and mouse CFUGM was examined at concentrations and times suggested by plasma clearance data derived from the results of a number of published studies. Our results suggest that the high concentrations of drug present in the plasma for short periods of time following infusion are only weakly cytotoxic towards the CFUGM when incubated for similar times. In contrast, there was a considerably greater cytotoxic effect when the drug was examined at low concentrations for periods similar to those described for the terminal phase of adriamycin clearance. The principal metabolite, adriamycinol, was poorly cytotoxic.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6466545      PMCID: PMC1976788          DOI: 10.1038/bjc.1984.182

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Clinical effects and pharmacokinetics of different dosage schedules of adriamycin.

Authors:  W A Creasey; L S McIntosh; T Brescia; O Odujinrin; G T Aspnes; E Murray; J C Marsh
Journal:  Cancer Res       Date:  1976-01       Impact factor: 12.701

2.  Stimulation by human placental conditioned medium of hemopoietic colony formation by human marrow cells.

Authors:  A W Burgess; E M Wilson; D Metcalf
Journal:  Blood       Date:  1977-04       Impact factor: 22.113

3.  Adriamycin metabolism in man. Evidence from urinary metabolites.

Authors:  S Takanashi; N R Bachur
Journal:  Drug Metab Dispos       Date:  1976 Jan-Feb       Impact factor: 3.922

4.  Plasma and urinary levels of adriamycin in man.

Authors:  R Rosso; C Ravazzoni; M Esposito; R Sala; L Santi
Journal:  Eur J Cancer       Date:  1972-08       Impact factor: 9.162

5.  Stimulation of in vitro granulocyte--macrophage colony formation by mouse heart conditioned medium.

Authors:  P V Byrne; W Heit; B Kubanek
Journal:  Br J Haematol       Date:  1978-10       Impact factor: 6.998

6.  Age dependence of the early-phase pharmacokinetics of doxorubicin.

Authors:  J Robert; B Hoerni
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

7.  Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites.

Authors:  R F Ozols; J K Willson; M D Weltz; K R Grotzinger; C E Myers; R C Young
Journal:  Cancer Res       Date:  1980-11       Impact factor: 12.701

8.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.

Authors:  S S Legha; R S Benjamin; B Mackay; M Ewer; S Wallace; M Valdivieso; S L Rasmussen; G R Blumenschein; E J Freireich
Journal:  Ann Intern Med       Date:  1982-02       Impact factor: 25.391

9.  [The pharmacokinetics of adriamycin and adriamycin-metabolites (author's transl)].

Authors:  G Ehninger; H J Stocker; B Proksch; K Wilms
Journal:  Klin Wochenschr       Date:  1980-09-15

10.  Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.

Authors:  R S Benjamin; C E Riggs; N R Bachur
Journal:  Cancer Res       Date:  1977-05       Impact factor: 12.701

View more
  4 in total

1.  Intracellular concentrations of anti cancer drugs in leukemic cells in vitro vs in vivo.

Authors:  B Sundman-Engberg; U Tidefelt; J Liliemark; C Paul
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  A pharmacokinetic study of adriamycin and 4'epi-adriamycin after simultaneous intra-arterial liver administration.

Authors:  S Eksborg; M Andersson; L Domellöf; U Lönroth
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

3.  The effect of etoposide on human CFU-GM.

Authors:  R Bailey-Wood; C M Dallimore; T J Littlewood; D P Bentley
Journal:  Br J Cancer       Date:  1985-10       Impact factor: 7.640

4.  Infusion-rate independent cellular adriamycin concentrations and cytotoxicity to human bone marrow clonogenic cells (CFU-GM).

Authors:  R Raijmakers; P Speth; T de Witte; P Linssen; J Wessels; C Haanen
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.